DelMar Pharmaceuticals Inc
Change company Symbol lookup
Select an option...
DMPI DelMar Pharmaceuticals Inc
FLR Fluor Corp
SPLK Splunk Inc
LB L Brands Inc
TEAM Atlassian Corporation PLC
GRAS Greenfield Farms Food Inc
CMS CMS Energy Corp
BAC Bank of America Corp
HPQ HP Inc
WNXDY Diebold Nixdorf AG
Go

*Nasdaq FSI: *Deficient: Issuer Failed to Meet NASDAQ Continued Listing Requirements

Health Care : Biotechnology | Small Cap Value
Based in CanadaCompany profile

DelMar Pharmaceuticals, Inc. is a clinical-stage drug development company. The Company focuses on the treatment of cancer. The Company is engaged in conducting clinical trials in the United States with its product candidate, VAL-083, as a treatment for glioblastoma multiforme (GBM), a form of brain cancer. VAL-083 is being evaluated in a Phase II clinical trial for the treatment of refractory GBM. In addition to its clinical development activities in the United States, the Company has obtained certain commercial rights to VAL-083 in China where it is approved as a chemotherapy for the treatment of chronic myelogenous leukemia (CML) and lung cancer. Its drug discovery research focuses on identifying validated clinical and commercial-stage compounds, and establishing a scientific rationale for development in orphan drug indications. VAL-083 is an alkylating agent, which crosses the blood-brain-barrier (BBB).

Price
Delayed
$2.49
Day's Change
-0.30 (-10.75%)
Bid
--
Ask
--
B/A Size
--
Day's High
2.78
Day's Low
2.41
Volume
(Heavy Day)

Today's volume of 96,954 shares is on pace to be much greater than DMPI's 10-day average volume of 171,765 shares.

96,954

Apple stock falls after HSBC downgrade

8:24 am ET December 4, 2018 (MarketWatch)
Print

Apple Inc. (AAPL) shares are down 2.1% in premarket trading Tuesday after HSBC analyst Erwan Rambourg downgraded the stock to hold from buy, writing that it was "too late to sell, too early to buy" Apple shares, which have fallen 19% over the past three months. "Apple has to innovate to ensure that the installed hardware base doesn't shrink," wrote Rambourg, who suggested three "complementary strategies" for the company. One is "horizontal diversification and geographic expansion," as services like Apple Pay are growing fast but could benefit from more reach, in Rambourg's view. Another approach would be adding new services and applications in areas such as augmented reality that would drive hardware improvement and excite current iPhone users. Rambourg's final strategy is "pure innovation" in new realms like autonomous driving, health, and augmented-reality glasses. He lowered his price target to $200 from $205, writing of an "undemanding valuation" but limited "immediate catalysts." The shares are down 11% over the past month, while the Dow Jones Industrial Average has risen 2.2%.

-Emily Bary; 415-439-6400; AskNewswires@dowjones.com

(END) Dow Jones Newswires

December 04, 2018 08:24 ET (13:24 GMT)

Copyright (c) 2018 Dow Jones & Company, Inc.

Earnings Calendar and Events Data provided by |Terms of Use| © 2019 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., , and

Copyright © 2019. All rights reserved.